• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Market for Rx-to-OTC Switches, 3rd Edition, The

$2,625.00 – $5,250.00

Clear
SKU: KLI833284 Categories: Over-the-Counter (OTC) Drugs, Pharmaceuticals Market Research, Prescription Drugs Market Reports Pages: 234
  • Description
  • Table of Contents
  • Latest reports

Description

Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate.

Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in a successful switch.

This study, the third time Kalorama has looked at the market, examines the current environment for OTC switches and pegs the market size and growth and competitive market share for various segments through 2007, identifying likely and unlikely switches and their potential.

Table of Contents

Executive Summary

  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting the Rx-to-OTC Switches Market
  • Leading Competitors

Introduction

  • Overview of the Over-the-Counter Market
  • Development of the Rx-to-OTC Drug Market
  • Rx-to-OTC Industry Structure

Allergy, Cough, Cold, And Sinus Products

  • Overview
    • Antihistamines
    • Decongestants
    • Cough Preparations
    • Mast Cell Stabilizers
    • Ophthalmic Preparations
  • Description of Conditions
    • Allergic Rhinitis
    • Common Cold
    • Sinusitis
    • Hives
    • Ocular Allergies
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market Analysis
    • Market Size and Forecast
    • Competitive Analysis

Analgesics, NSaids, And Topical Pain Relievers

  • Overview
    • Analgesics
    • Nonsteroidal Anti-inflammatory Drugs
    • Topical Pain Relievers and Other Similar Products
  • Description of Conditions
    • Pain
    • Inflammation
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market Analysis
    • Market Size and Forecast
    • Competitive Analysis

Anti-Infectives

  • Overview
    • Antibiotics
    • Antifungals
    • Antivirals
    • Antiparasitics
  • Description of Conditions
    • Vaginal Infections
    • Athlete’s Foot
    • Jock Itch
    • Ringworm
    • Dandruff
    • Scabies and Pediculosis
    • Pinworm
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market Analysis
    • Market Size and Forecast
    • Competitive Analysis

Gastrointestinal Drugs

  • Overview
  • Description of Conditions
    • Nausea
    • Diarrhea
    • Heartburn
    • Acid reflux
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market and Competitive Analysis
    • Market Size and Forecast
    • Competitive Analysis

Smoking Cessation

  • Overview
  • Description of Conditions
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market Analysis
    • Market Size and Forecast
    • Competitive Analysis

Miscellaneous Drugs

  • Overview
    • Dental Rinses and Fluorides
    • Hair Growth Products
    • Rectal Ointments
    • Sleep Aids
  • Description of Conditions
    • Dental Carries
    • Hereditary Hair Loss
    • Hemorrhoids
    • Sleeplessness
  • Conditions with Possible Future OTC Treatments
    • Elevated Cholesterol
    • Osteoporosis
    • Acne Vulgaris
    • Menopause and Hormone Replacement
    • Pregnancy Prevention
  • Prevalence and Incidence
  • Product Analysis
    • Current OTC Switched Products
    • Prescription Products with Anticipated OTC Approvals
  • Market Analysis
    • Market Size and Forecast
    • Competitive Analysis

Total Market Summary

  • Overview
  • Total market Size and Forecast
    • Markets by Segments
  • Competitive Analysis
  • Market Analysis

Issues And Trends Affecting The Rx-To-OTC Market

  • Introduction
  • Regulatory Authorities
  • A Third Class of Drug
  • Impact on the Insurance Company
  • Pharmacists Role
  • Impact on the Prescription Drug Manufacturer
  • Strategies for Continued Product Growth—Dual Status Switching
  • Impact on the Consumer
    • Direct-to-Consumer Advertising
    • Consumer Purchasing Trends
  • Patent Expiration
  • Labeling Changes

Company Profiles

Brand Company Profiles

  • Bayer Consumer Care
  • GlaxoSmithKline Consumer Healthcare
  • Johnson & Johnson
  • Merck Consumer Pharmaceuticals Company
  • McNeil Consumer & Specialty Pharmaceuticals
  • Novartis Consumer Health, Inc.
  • Personal Products Company
  • Pfizer Consumer Healthcare
  • Pharmacia Consumer Healthcare
  • Procter & Gamble Company, Health Care Division
  • Schering-Plough HealthCare Products
  • Wyeth Consumer Health Care

Generic and Private Label Company Profiles

  • Alpharma U.S. Human Pharmaceuticals (USHP)
  • IVAX Pharmaceuticals, Inc.
  • Perrigo Company
  • Watson Pharmaceuticals, Inc.

Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: The Total U.S. Market for Over-the-Counter Switches 1997-2007
  • Figure 1-1: The U.S. Market for Rx-to-OTC Switches Revenues by Type 1997-2007
  • Table 1-2: Leading Suppliers’ Significant Segments of Participation within the U.S. Market for Rx-to-OTC Switches, 2002

Chapter Two: Introduction

  • Table 2-1: OTC Retail Sales, 1976-2001
  • Table 2-2: Rx-to-OTC Switches Approved by the FDA 1976-2003
  • Table 2-3: Statistics for Selected Rx-to-OTC Switches
  • Table 2-4: Estimated OTC Sales by Product Type and Percent of Sales Attributed to Rx-to-OTC Switched Ingredients
  • Table 2-5: U.S. Population by Sex and Selected Age Group, 1997-2017
  • Table 2-6: Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons Based on 2002 Data
  • Figure 2-1: Healthcare Industry Inflation Rates Healthcare Industry Consumer Price Index Comparisons Based on 2002 Data

Chapter Three: Allergy, Cough, Cold, And Sinus Products

  • Table 3-1: United States Incidence of Allergy, Cough, Cold, Sinus Conditions 2002
  • Figure 3-1: United States Incidence of Allergy, Cough, Cold, Sinus Conditions, Superimposed on Total Population, 2002
  • Table 3-2: Allergy, Cough, Cold, Sinus Product Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 3-3: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 3-4: The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 1997-2007
  • Figure 3-2: The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Product Revenues 1997-2007
  • Table 3-5: The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Products Revenues by Type 1997-2007
  • Table 3-6: The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and Sinus Products Distribution of Revenues by Product Type 1997-2007
  • Figure 3-3: The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, by Product Type and Revenues, 1997-2007
  • Figure 3-4: The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, by Percent and Product Type, 2002
  • Table 3-7: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2002
  • Figure 3-5: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold, and Sinus Products, 2002

Chapter Four: Analgesics, Nsaids, And Topical Pain Relievers

  • Table 4-1: United States Incidence of Conditions with Pain and Inflammatory Symptoms 2002
  • Figure 4-1: United States Incidence of Conditions with Pain and Inflammatory Symptoms Superimposed on Total Population, 2002
  • Table 4-2: Analgesics, NSAIDs and Other Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 4-3: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 4-4: The U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs Total Revenues 1997-2007
  • Figure 4-2: The U.S. Market for Rx-to-OTC Switches: Analgesics, NSAIDs, and Other Drugs, 1997-2007
  • Table 4-5: The U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs Revenues by Product Type 1997-2007
  • Table 4-6: The U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs Distribution of Revenues by Product Type 1997-2007
  • Figure 4-3: The U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs Revenues by Product Type 1997-2007
  • Figure 4-4: The U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs Distribution of Revenues by Product Type 2002
  • Table 4-7: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs 2002
  • Figure 4-5: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Analgesics, NSAIDs, and Other Drugs 2002

Chapter Five: Anti-Infectives

  • Table 5-1: United States Yearly Incidence of Infections, 2002
  • Figure 5-1: United States Yearly Incidence of Infections Superimposed on Total Population, 2002
  • Table 5-2: Anti-infectives Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 5-3: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 5-4: The U.S. Market for Rx-to-OTC Switches Anti-infectives 1997-2007
  • Figure 5-2: The U.S. Market for Rx-to-OTC Switches Anti-infectives, 1997-2007
  • Table 5-5: The U.S. Market for Rx-to-OTC Switches Anti-infectives by Product Type 1997-2007
  • Table 5-6: The U.S. Market for Rx-to-OTC Switches, Anti-infectives Distribution of Revenues by Product Type 1997-2007
  • Figure 5-3: The U.S. Market for Rx-to-OTC Switches Anti-infectives by Product Type, 1997-2007
  • Figure 5-4: The U.S. Market for Rx-to-OTC Switches, Anti-infectives Revenue Distribution by Product Type 2002
  • Table 5-7: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives 2002
  • Figure 5-5: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switched Anti-infectives 2002

Chapter Six: Gastrointestinal Drugs

  • Table 6-1: United States Incidence of Gastrointestinal Conditions 2002
  • Figure 6-1: United States Incidence of Gastrointestinal Conditions Superimposed on General Population 2002
  • Table 6-2: Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 6-3: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 6-4: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 1997-2007
  • Figure 6-2: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 1997-2007
  • Table 6-5: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs by Product Type 1997-2007
  • Table 6-6: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs Distribution of Revenues by Product Type 1997-2007
  • Figure 6-3: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs by Product Type 1997-2007
  • Figure 6-4: The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs Distribution of Revenues by Product Type 2002
  • Table 6-7: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2002
  • Figure 6-5: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Gastrointestinal Drugs 2002

Chapter Seven: Smoking Cessation

  • Table 7-1: United States Cigarette Usage in Percent by Age Group, 2002
  • Figure 7-1: United States Cigarette Usage in Percent by User Type 2002
  • Table 7-2: Lung Cancer in the United States Estimated New Cases and Deaths 2002
  • Table 7-3: Smoking Cessation Product Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 7-4: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 7-5: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 1997-2007
  • Figure 7-2: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 1997-2007
  • Table 7-6: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs Revenues by Product Type 1997-2007
  • Table 7-7: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs Distribution of Revenues by Product Type 1997-2007
  • Figure 7-3: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs Revenues by Product Type 1997-2007
  • Figure 7-4: The U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs Distribution of Revenue by Product Type 2002
  • Table 7-8: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2002
  • Figure 7-5: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Smoking Cessation Drugs 2002

Chapter Eight: Miscellaneous Drugs

  • Table 8-1: United States Incidence of Miscellaneous Conditions for Which There Are Potential Rx-to-OTC Switches 2002
  • Table 8-2: Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status by Trade Name, Distributor, and Date of OTC Approval
  • Table 8-3: Prescription Drugs with Anticipated OTC Approval by Ingredient, Trade Name, Distributor and Current Activity
  • Table 8-4: The U.S. Market for Rx-to-OTC Switches Miscellaneous Drugs Revenues by Product Type 1997-2007
  • Table 8-5: The U.S. Market for Rx-to-OTC Switches Miscellaneous Drugs Distribution of Revenues by Product Type 1997-2007
  • Figure 8-1: The U.S. Market for Rx-to-OTC Switches Miscellaneous Drugs Revenues by Product Type 1997-2007
  • Figure 8-2: The U.S. Market for Rx-to-OTC Switches Miscellaneous Dugs Distribution of Revenues by Product Type 2002
  • Table 8-6: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Miscellaneous Drugs 2002
  • Figure 8-3: Leading Suppliers’ Shares of the U.S. Market for Rx-to-OTC Switches Miscellaneous Drugs 2002

Chapter Nine: Total Market Summary

  • Table 9-1: The U.S. Market for Rx-to-OTC Switches 1997-2007
  • Figure 9-1: The U.S. Market for Rx-to-OTC Switches, 1997-2007
  • Table 9-2: The U.S. Market for Rx-to-OTC Switches by Type, 1997-2007
  • Table 9-3: The U.S. Market for Rx-to-OTC Switches Revenue Distribution by Segment 1997-2007
  • Figure 9-2: The U.S. Market for Rx-to-OTC Switches by Type and Revenues, 1997-2007
  • Figure 9-3: The U.S. Market for Rx-to-OTC Switches by Type and Percent Distribution, 1997-2007
  • Figure 9-4: The U.S. Market for Rx-to-OTC Switches by Percent and Segment, 2002
  • Table 9-4: Leading Suppliers Significant Segments of Participation within the U.S. Market for Rx-to-OTC Switches, 2002

Chapter Ten: Issues and Trends Affecting the Rx-to-OTC Market

Figure 10-1: Typical Pharmacist-Consumer OTC Drug Counseling Session

Table 10-1: Health Insurance Coverage Status by Selected Characteristics, 1990-2000

Table 10-2: Average Annual Expenditures per Consumer Unit for Healthcare 1990-2000

Table 10-3: Estimated Direct-to-Consumer Advertising Expenditures by Drug and Marketer

 

    The Market for Rx-to-OTC Switches, 8th Edition
    May 5, 2022
    Global Over-the-Counter (OTC) Drug Markets
    January 23, 2018
    The US Market for Rx to OTC Switches, Forecasts to 2019, 7th Edition
    February 2, 2015
    The U.S. Market for Rx to OTC Switches, 6th Edition
    January 11, 2013

Related products

  • Placeholder image

    World Market for Anti-infectives Volume III: The World Market for Antiviral Medications, The

    $1,875.00 – $3,750.00
  • Placeholder image

    U.S. Market for OTC Diet Aids, The

    $3,000.00 – $6,000.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00
  • Placeholder image

    Type II Diabetes: The 45 Market in the United States for Drugs and Diagnostics

    $2,995.00 – $5,990.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • How Globalization and Climate Change Impact COVID-19 and the IVD Market September 20, 2023
  • IVD Trends 2023-2028: Emerging Growth Markets in Asia, Latin America, and the Middle East September 15, 2023
  • Worldwide IVD: 8 Key Trends to Watch in $106 Billion Market September 6, 2023
  • The Wide-Reaching Potential of Artificial Intelligence in Healthcare August 28, 2023
  • IVD for Pets: A $2.7 Billion Global Market July 24, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Diabetes in Japan: The Markets for Monitoring, Insulin, Oral Hypoglycemics,...Wound Care Markets: Volume I: Skin Ulcers
Scroll to top